Literature DB >> 9375282

Classification criteria for the idiopathic inflammatory myopathies.

I N Targoff1, F W Miller, T A Medsger, C V Oddis.   

Abstract

Inasmuch as the clinical features of the idiopathic inflammatory myopathies are not easily differentiated from those of other similar rheumatic and neurologic conditions, diagnosis is often difficult. Various classification criteria for polymyositis and dermatomyositis have been suggested by a number of investigators. The most commonly accepted and used criteria include symmetric proximal muscle weakness, serum elevations of muscle enzymes, the classic electromyographic and muscle biopsy findings of inflammatory myopathy, and the typical skin rash of dermatomyositis. Although these criteria are clinically useful, they can result in misdiagnoses and inappropriate therapies. They also result in heterogeneous patient groups being selected for clinical and laboratory studies. Furthermore, they do not include recent findings related to the myositis-specific autoantibodies and magnetic resonance imaging of muscle that have been found to be important adjuncts in assessing patients with muscle weakness or elevations of muscle enzymes. A modification to the Bohan and Peter criteria is proposed to include myositis-specific autoantibodies and magnetic resonance imaging. This proposal could initiate productive discussions and investigations of the sensitivity and specificity of new classification criteria for myositis and could ultimately enhance our treatment capabilities.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9375282     DOI: 10.1097/00002281-199711000-00008

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  51 in total

Review 1.  Classification of myositis.

Authors:  Ingrid E Lundberg; Marianne de Visser; Victoria P Werth
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

2.  Diagnosis and treatment of the idiopathic inflammatory myopathies.

Authors:  David J Gazeley; Mary E Cronin
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-12       Impact factor: 5.346

Review 3.  Idiopathic inflammatory myopathies-a review.

Authors:  Jonathan Jones; Robert Wortmann
Journal:  Clin Rheumatol       Date:  2015-02-14       Impact factor: 2.980

Review 4.  The Clinical and Histological Spectrum of Idiopathic Inflammatory Myopathies.

Authors:  Ilaria Cavazzana; Micaela Fredi; Carlo Selmi; Angela Tincani; Franco Franceschini
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 5.  Immune-Mediated Necrotizing Myopathy: Update on Diagnosis and Management.

Authors:  Pari Basharat; Lisa Christopher-Stine
Journal:  Curr Rheumatol Rep       Date:  2015-12       Impact factor: 4.592

6.  Activation of osmolyte pathways in inflammatory myopathy and Duchenne muscular dystrophy points to osmoregulation as a contributing pathogenic mechanism.

Authors:  Boel De Paepe; Jean-Jacques Martin; Sandrine Herbelet; Cecilia Jimenez-Mallebrera; Estibaliz Iglesias; Cristina Jou; Joachim Weis; Jan L De Bleecker
Journal:  Lab Invest       Date:  2016-06-20       Impact factor: 5.662

7.  Myopathy with antibodies to the signal recognition particle: clinical and pathological features.

Authors:  T Miller; M T Al-Lozi; G Lopate; A Pestronk
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-10       Impact factor: 10.154

8.  Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis.

Authors:  Puja Srivastava; Sanjay Dwivedi; Ramnath Misra
Journal:  Rheumatol Int       Date:  2016-05-14       Impact factor: 2.631

Review 9.  Is statin-induced myositis part of the polymyositis disease spectrum?

Authors:  Jemima Albayda; Andrew L Mammen
Journal:  Curr Rheumatol Rep       Date:  2014-08       Impact factor: 4.592

Review 10.  Paraneoplastic dermatological manifestation of gastrointestinal malignancies.

Authors:  Lyubomir A Dourmishev; Peter V Draganov
Journal:  World J Gastroenterol       Date:  2009-09-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.